Coronavirus: legal and regulatory issues for the life sciences sector

In the current COVID-19 crisis, governments around the world are turning to businesses and research organisations in the life sciences sector to assist in meeting the challenge. We are seeing new levels of innovation and collaboration around the development, at real pace, of vaccines, diagnostic kits and medical devices, as...

Supporting clinical trials during pandemic with home nursing

In response to the COVID-19 outbreak, A4P Bio Logistics has collaborated with Wren Healthcare to offer a one-stop solution for CRO’s, sponsors and study sites to support the continuation of clinical trial studies through home nursing and direct-to-patient IMP and sample logistics. It has become increasingly difficult for patients to...

Medical Technologies Innovation Facility Announcement

The Nottingham based Medical Technologies Innovation Facility (MTIF) is delighted to announce three key appointments to its leadership team. Jacqui Hayes joins us with over thirty years of experience in medical technology and pharmaceutical business development. Using her expertise in building collaborative partnerships Jacqui will develop our commercial offering enabling...

Nottingham engineers produce certified 3D printed face shields for NHS

Engineers at the University of Nottingham have designed a PPE face shield with CE approval that they are 3D printing at scale for healthcare workers to use in the fight against COVID-19. Using the latest in Additive Manufacturing (3D printing) technology and materials at the University’s Centre for Additive Manufacturing,...

Upperton Invest £500K in their Tablet Formulation and Manufacturing Capabilities

Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO) have invested £500K in significantly expanding their tablet manufacturing capabilities with the addition of tablet processing equipment for wet granulation, roller compaction, tablet compression, hardness testing, dedusting, weight sorting and tablet coating throughout 2019 and 2020. This investment of...

Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases....

Medilink EM Patron Spotlight: Morningside Pharmaceuticals

Medilink EM works with life science businesses, academic institutions and the NHS across the East Midlands, to help new and existing life science companies to develop and grow. In addition to the business support programmes it helps to deliver, Medilink EM provides a range of valuable benefits for its members,...

The impact of COVID-19 on innovation

Times of crisis are sometimes accompanied by huge spikes in innovation. Much like a fight-or-flight response in individuals, a knee-jerk reaction to adverse conditions for some organisations is to develop new technology as fast as possible. However, it very much depends on the nature of the adversity. The impact of...